Senior Scientist / Scientist, In Vivo Pharmacology

The role

This person will design and execute in vivo pharmacology studies to evaluate epigenetic reprogramming therapeutics. They will lead in vivo pharmacology strategies and collaborate with therapeutic area teams to drive candidate selection.

What you will do

• Design, execute, and interpret in vivo pharmacology studies across multiple disease models and therapeutic programs
• Collaborate with Epigenetic Editing, Predictive Modeling, and other therapeutic area teams
• Develop and refine animal models of aging and age-related disease
• Oversee study design, protocol development, and CRO/vendor relationships
• Analyze and interpret in vivo data to drive pre-clinical decision making
• Contribute to regulatory-enabling study design and documentation

Required qualifications

• Ph.D. in pharmacology, physiology, biology or a related field or equivalent industry experience (5+ years for Scientist; 8+ years for Senior Scientist)
• Demonstrated experience designing and executing in vivo pharmacology studies (PK, PD, efficacy, dose-range finding) in rodent models
• Experience with study design, dosing regimens, and route-of-administration selection
• Experience analyzing and interpreting in vivo pharmacology data to inform program decisions
• Experience leading project workflows and providing technical mentorship to junior laboratory staff
• History of contributing to a drug development program at the pre-clinical or clinical development stage

Nice to have

• Experience with liver biology, hepatic disease models, or hepatocyte-directed delivery
• Experience with nucleic acid or viral vector delivery in vivo
• Experience with GLP-enabling or IND-enabling study design
• Experience with single cell genomics or pooled screening approaches applied to in vivo readouts

Benefits

• Health, dental, and vision insurance
• 401(k) with company match
• Paid parental leave
• 20 days/year PTO + holidays
• Meals and snacks on-site

About the company

NewLimit is a biotechnology company working to radically extend human healthspan. They develop medicines to treat age-related diseases by reprogramming the epigenome.